Skip to content

Norwegian Study on District Treatment of ST-Elevation Myocardial Infarction

Benefits and Costs in Two Different Strategies for Treating Acute Myocardial Infarction With ST-Elevation.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00161005
Enrollment
266
Registered
2005-09-12
Start date
2005-02-28
Completion date
2009-12-31
Last updated
2009-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Infarction

Keywords

Acute myocardial infarction, Fibrinolysis, Health effects /Quality of life

Brief summary

In the district areas of Norway patients with acute myocardial infarction with ST-elevation, are treated with thrombolysis. An increasing part of them receives thrombolysis before arrival to the local hospital.Usually these patients have been sent to an invasive center if thrombolysis fails or the patient gets ischemic symptoms during the stay. This study will compare this strategy against immediate transportation to an invasive center after the patient has received thrombolysis.

Interventions

PROCEDUREPCI

Immediate transport to invasive center after thrombolysis

Sponsors

Helse Innlandet
CollaboratorUNKNOWN
Ullevaal University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Duration of painless than 6 hours. * ST-segment elevation of at least 0.1 mV in two or more extremity leads or at least 0.2 mV in two or more precordial leads. * The patient is getting thrombolysis. * Time to reach an invasive center is more than 1 hour. * Age 18-75 years.

Exclusion criteria

* Known serious renal failure (creatinin \> 250 mmol/l) * Pregnancy * Cardiogenic chock * Life threatening arrythmias * Other serious diseases with life expectancy less than 1 year. * Inability to perform an informed consent

Design outcomes

Primary

MeasureTime frame
Death , myocardial infarction ,stroke or ischemia during 12 months.12 months
Costs during 12 months.12 months

Secondary

MeasureTime frame
Size of infarction.3 months
Complications1 month

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 8, 2026